
Sign up to save your podcasts
Or


Dr. Monty Pal shares highlights from Day 3 of the 2026 ASCO Annual Meeting, including new research for the treatment of advanced CRC and mCRPC, TIL cell therapy in advanced non-uveal melanoma, and an ultra-low dose immunotherapy trial in head and neck squamous cell carcinoma.
LINK TO FULL TRANSCRIPT
By American Society of Clinical Oncology (ASCO)4.6
5656 ratings
Dr. Monty Pal shares highlights from Day 3 of the 2026 ASCO Annual Meeting, including new research for the treatment of advanced CRC and mCRPC, TIL cell therapy in advanced non-uveal melanoma, and an ultra-low dose immunotherapy trial in head and neck squamous cell carcinoma.
LINK TO FULL TRANSCRIPT

321 Listeners

504 Listeners

39 Listeners

65 Listeners

756 Listeners

121 Listeners

2,262 Listeners

818 Listeners

187 Listeners

46 Listeners

32 Listeners

828 Listeners

59 Listeners

195 Listeners

45 Listeners